The Latest
-
Getty Images
Amid a flurry of biotech deals, China looks to keep innovation at home
The country's new regulatory pathway promises to accelerate access to advanced therapies for Chinese patients, but may change the licensing game for foreign companies.
-
Permission granted by Rivus Pharmaceuticals
Q&A // First 90 DaysWith a promising MASH asset, muscle-sparing GLP-1 and new CEO, Rivus gets ready to make its mark
Rivus Pharmaceuticals’ CEO Jorge Bartolome said the biotech is on track to build a “truly differentiated” cardiometabolic portfolio.
-
Getty Images
Will obesity drugs save Pfizer from its post-COVID slump?
With COVID’s windfall over and blockbuster patents expiring, Pfizer is looking for a comeback with its newly built obesity pipeline.
-
Getty Images
3 potential takeover targets in obesity
Momentum is building to bring a next-generation weight loss drug to market, which could set up these three biotechs to strike a deal with a larger pharma.
-
Don Murray via Getty Images
GSK, Takeda and others notch key clinical wins in tough-to-treat diseases
From hepatitis B to melanoma, recent study results show innovative approaches are gaining ground.
-
Permission granted by Bristol Myers Squibb
BMS under pressure in schizophrenia; Summit/Akeso on a winning streak
While the large pharma’s new drug Cobenfy has stumbled in schizophrenia, it could find new life in Alzheimer’s disease
-
Getty Images
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.
-
Getty Images
House bill aims to crack down on China biotech deals
A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S. fears that China’s drugmaking progress may threaten national security.
-
Getty Images
When the ISS comes down, will its drug R&D be lost in space?
As NASA prepares to bring its hallmark space lab back to Earth, a host of private companies are emerging to fill the gap.
-
Getty Images
As amyloid falls out of favor, here’s where Alzheimer’s R&D is headed next
The Alzheimer’s pipeline is growing as drug developers put more emphasis on inflammation, tau and biomarkers.
-
Christopher Furlong via Getty Images
AstraZeneca aims for a new blockbuster run in cardio disease
With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight management and beyond, according to a company exec.
-
Getty Images
Longevity science picks up steam in pharma
Fueled by multi-billion-dollar valuations and a deeper understanding of aging biology, the field is rapidly moving past the hype and into the clinic.
-
Getty Images
Can AI crack pharma’s drug repurposing goldmine?
With AI now capable of analyzing decades’ worth of data, FDA is pushing pharma to leverage its “enormous, untapped value” by repurposing drugs.
-
Getty Images
Vertex’s Journavx made history, but left a void in the pain space
The search is still on for an opioid alternative and many companies are betting on ion channel drugs to fill the gap.
-
Getty Images
The ‘secret sauce’ for hiring for biotech CEOs
Biotech company architect Stella Vnook shares her formula for finding the right chief executives.
-
Getty Images
Can a chaotic FDA still deliver on faster drug development?
As leadership changes create more instability at the agency, here's what it'll take to keep speedier drug approvals on track.
-
Permission granted by Bristol Myers Squibb
Q&AIn Alzheimer’s, Bristol Myers sees big promise beyond amyloid
Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.
-
Getty Images
Who’s winning pharma’s innovation race? The rankings are out.
While Eli Lilly reigns supreme, Idea Pharma’s annual R&D ranking reveals which other large pharmas are on the rise — and which are stumbling.
-
Permission granted by American Biotech Innovation Alliance
Q&AChina’s biotech rise sparks new US industry alliance
The nonprofit is aiming to inspire a new moonshot effort that helps the U.S. maintain its position as a drug innovation leader.
-
Getty Images
Big Pharma is gambling on specialized R&D. Will it pay off?
Large pharma companies are taking bigger swings on fewer targets, which can be a risky strategy.
-
Courtesy of Regeneron Pharmaceuticals
Regeneron immunotherapy combo comes up short in melanoma trial
A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.
-
Getty Images
Summer reads with unexpected lessons for biopharma leaders
From an inspiring rags-to-riches journey to a heroic rescue story at sea, here are a few books recommended by biopharma execs and what they can teach about leadership.
-
Getty Images
Race intensifies to lead next wave of obesity drugs as trial results loom
As next-generation GLP-1 contenders rise, key readouts are on the way from Pfizer, Viking Therapeutics and Eli Lilly.
-
Permission granted by Ovid Therapeutics
Q&AFormer Ovid CEO Dr. Jeremy Levin’s rallying cry for biotech
The long-time pharma exec is on a quest with a new book and bold message for biotech leaders and U.S. lawmakers.
-
Alex Wong via Getty Images
Sanofi’s vaccine bump; the new FDA commish
A look at how vaccine makers are scraping by, and at the incoming acting FDA head, Kyle Diamantas.
